Tidal Investments LLC Has $1.66 Million Stake in Repligen Co. (NASDAQ:RGEN)

Tidal Investments LLC increased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 142.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,149 shares of the biotechnology company’s stock after purchasing an additional 6,558 shares during the quarter. Tidal Investments LLC’s holdings in Repligen were worth $1,659,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in RGEN. Champlain Investment Partners LLC boosted its holdings in Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after purchasing an additional 850,345 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in Repligen by 240.5% during the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock worth $75,866,000 after purchasing an additional 425,061 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after purchasing an additional 237,884 shares during the last quarter. Conestoga Capital Advisors LLC lifted its stake in Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after acquiring an additional 199,322 shares during the last quarter. Finally, DF Dent & Co. Inc. lifted its stake in Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after acquiring an additional 139,615 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Wolfe Research assumed coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Wells Fargo & Company assumed coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target for the company. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday. They issued a “hold” rating and a $165.00 price target for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Finally, Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday. They issued a “hold” rating and a $165.00 price target for the company. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $185.20.

Repligen Stock Performance

NASDAQ RGEN opened at $158.14 on Wednesday. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The stock has a market cap of $8.86 billion, a PE ratio of -427.41, a P/E/G ratio of 4.64 and a beta of 0.96. The firm has a 50-day moving average of $143.15 and a 200-day moving average of $141.68. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same period last year, the firm earned $0.23 earnings per share. Repligen’s revenue for the quarter was up 9.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Repligen Co. will post 1.54 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.